FR10C0048I2 - Nouvelle proteine et methode de production associee - Google Patents

Nouvelle proteine et methode de production associee

Info

Publication number
FR10C0048I2
FR10C0048I2 FR10C0048C FR10C0048C FR10C0048I2 FR 10C0048 I2 FR10C0048 I2 FR 10C0048I2 FR 10C0048 C FR10C0048 C FR 10C0048C FR 10C0048 C FR10C0048 C FR 10C0048C FR 10C0048 I2 FR10C0048 I2 FR 10C0048I2
Authority
FR
France
Prior art keywords
protein
substance
antibody
dna
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0048C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27525882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0048(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of FR10C0048I1 publication Critical patent/FR10C0048I1/fr
Application granted granted Critical
Publication of FR10C0048I2 publication Critical patent/FR10C0048I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
FR10C0048C 1997-04-15 2010-11-25 Nouvelle proteine et methode de production associee Active FR10C0048I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP9780897 1997-04-15
JP15143497 1997-06-09
JP21789797 1997-08-12
JP22480397 1997-08-21
JP33224197 1997-12-02
PCT/JP1998/001728 WO1998046644A1 (en) 1997-04-15 1998-04-15 Novel protein and process for producing the same

Publications (2)

Publication Number Publication Date
FR10C0048I1 FR10C0048I1 (ja) 2011-01-14
FR10C0048I2 true FR10C0048I2 (fr) 2013-08-16

Family

ID=27525882

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0048C Active FR10C0048I2 (fr) 1997-04-15 2010-11-25 Nouvelle proteine et methode de production associee

Country Status (21)

Country Link
US (7) US7527790B2 (ja)
EP (3) EP1657255B1 (ja)
JP (7) JP3523650B2 (ja)
KR (1) KR100496063B1 (ja)
CN (1) CN1138786C (ja)
AT (1) ATE328006T1 (ja)
AU (1) AU735355B2 (ja)
CA (2) CA2257247C (ja)
CY (1) CY2010017I2 (ja)
DE (2) DE122010000049I1 (ja)
DK (1) DK0911342T4 (ja)
ES (1) ES2263204T5 (ja)
FR (1) FR10C0048I2 (ja)
HU (3) HU229841B1 (ja)
IL (1) IL127115A (ja)
LU (1) LU91759I2 (ja)
NO (2) NO322632B1 (ja)
NZ (1) NZ332995A (ja)
PT (1) PT911342E (ja)
RU (1) RU2238949C2 (ja)
WO (1) WO1998046644A1 (ja)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
EP1995318A1 (en) 1996-12-13 2008-11-26 Schering Corporation Mammalian cell surface antigens; related reagents
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DK0911342T4 (da) * 1997-04-15 2013-07-29 Daiichi Sankyo Co Ltd Nyt protein og fremgangsmåde til fremstilling deraf
ATE363533T1 (de) * 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
ES2317694T3 (es) * 1998-05-14 2009-04-16 Immunex Corporation Metodo para inhibir la actividad osteoclastica.
RU2223782C2 (ru) 1998-10-28 2004-02-20 Санкио Компани, Лимитед Средство для лечения патологического костного метаболизма
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
DE60134459D1 (de) † 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
JP4854174B2 (ja) 2000-09-22 2012-01-18 イミュネックス・コーポレーション ＮＦ−κＢの受容体活性化剤のアゴニストまたはアンタゴニストのスクリーニングアッセイ法
WO2002062990A1 (fr) * 2001-02-07 2002-08-15 Sankyo Company, Limited Anticorps et utilisation de cet anticorps
WO2002079256A1 (fr) * 2001-03-26 2002-10-10 Sankyo Company, Limited Anticorps et son utilisation
AU2002253133B2 (en) 2001-04-03 2008-02-28 Societe Des Produits Nestle S.A. Osteoprotegerin in milk
DE122010000047I1 (de) 2001-06-26 2011-05-05 Amgen Fremont Inc Antikörper gegen opgl
MXPA04009681A (es) 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
JP2006521084A (ja) * 2002-12-10 2006-09-21 シェーリング−プラウ・リミテッド イヌｒａｎｋｌならびにイヌｒａｎｋｌを調製および使用するための方法
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
EP1659918B1 (en) 2003-08-08 2009-01-14 Amgen Fremont Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2311873B1 (en) 2004-01-07 2018-08-29 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US20070190560A1 (en) * 2006-02-13 2007-08-16 Olga Ornatsky Element-tagged olignucleotide gene expression analysis
US8257933B2 (en) 2006-05-12 2012-09-04 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
KR101235439B1 (ko) 2006-10-11 2013-02-20 오리엔탈 이스트 컴파니 리미티드 가용형 ｒａｎｋｌ과 에피토프 태그의 융합 단백질을 포함하는 시약
CN101772351B (zh) 2007-06-05 2013-01-02 东方酵母工业株式会社 新的骨量增加药
HUE025262T2 (en) 2007-10-11 2016-02-29 Daiichi Sankyo Co Ltd Antibody targeting osteoclast-linked Siglec-15 protein
US8778359B2 (en) * 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
EP2343087B1 (en) 2008-09-30 2018-07-18 Oriental Yeast Co., Ltd. Novel inducer of chondrocyte proliferation and differentiation
CN102361632A (zh) * 2009-03-30 2012-02-22 弗·哈夫曼-拉罗切有限公司 避免玻璃雾化的方法
US8575316B2 (en) 2009-04-09 2013-11-05 Daiichi Sankyo Company, Limited Anti-Siglec-15 antibody
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
CN103237813A (zh) 2010-10-05 2013-08-07 第一三共株式会社 靶向破骨细胞相关蛋白涎免凝集素-15的抗体
JPWO2012050154A1 (ja) * 2010-10-13 2014-02-24 学校法人東京女子医科大学 抗ｖｄａｃ抗体を含有する破骨細胞形成抑制剤
WO2012133914A1 (ja) 2011-03-31 2012-10-04 オリエンタル酵母工業株式会社 Ranklアンタゴニストを含む癌免疫増強剤
JP6346602B2 (ja) * 2012-03-21 2018-06-20 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒトリンパ器官由来の抑制性ストローマ細胞の単離および使用
AU2013241003A1 (en) 2012-03-30 2014-10-16 Daiichi Sankyo Company,Limited Cdr-modified anti-siglec-15 antibody
EP2875051B1 (en) 2012-07-19 2019-02-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies
CN102788817B (zh) * 2012-08-24 2015-04-08 中煤科工集团重庆研究院有限公司 超低温环境下可燃气体爆炸特性实验研究方法
WO2015018421A1 (en) 2013-08-07 2015-02-12 Rigshospitalet Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
EP3086780A4 (en) 2013-12-27 2017-08-09 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
AU2016422911B2 (en) * 2016-09-13 2021-04-01 E&S Healthcare Co., Ltd. Monoclonal antibody specifically binding to thioredoxin 1, and use thereof
CN108410990B (zh) * 2018-05-30 2021-07-06 中国医学科学院北京协和医院 Igfbp3在制备诊断i型神经纤维瘤合并脊柱畸形病产品中的应用
CN112552382A (zh) * 2020-01-22 2021-03-26 天津科技大学 一种信号肽突变体及其用途
CN111333709B (zh) * 2020-03-17 2023-09-08 吉林大学 旋毛虫肌幼虫期丝氨酸蛋白酶抑制剂的b细胞表位多肽、杂交瘤细胞株、单克隆抗体及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
EP0192658A4 (en) 1984-07-30 1987-07-13 Salk Inst For Biological Studi RETROVIRAL GENE TRANSFER VECTORS.
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5623053A (en) * 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ES2142341T3 (es) 1992-04-30 2000-04-16 Amgen Inc Metodos de tratamiento de las enfermedades inducidas por la interleuquina-1 y el factor de necrosis tumoral.
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JPH09502614A (ja) 1993-09-14 1997-03-18 メルク エンド カンパニー インコーポレーテッド 新規ヒト蛋白質チロシンホスファターゼをコードするｃＤＮＡ
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
AU4440496A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU6090896A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5662948A (en) * 1996-01-29 1997-09-02 Chrysler Corporation Adjustable and removable trimline inserts for a molding tool
US6750091B1 (en) * 1996-03-01 2004-06-15 Micron Technology Diode formation method
JPH1057071A (ja) * 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
EP1995318A1 (en) * 1996-12-13 2008-11-26 Schering Corporation Mammalian cell surface antigens; related reagents
EP0951546A2 (en) 1996-12-20 1999-10-27 The Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DK0911342T4 (da) 1997-04-15 2013-07-29 Daiichi Sankyo Co Ltd Nyt protein og fremgangsmåde til fremstilling deraf
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
CA2288351A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
ES2317694T3 (es) 1998-05-14 2009-04-16 Immunex Corporation Metodo para inhibir la actividad osteoclastica.
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
JP2003508491A (ja) 1999-09-03 2003-03-04 アムジエン・インコーポレーテツド 癌および癌に関連する骨損失の予防または治療のための組成物および方法
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DE122010000047I1 (de) 2001-06-26 2011-05-05 Amgen Fremont Inc Antikörper gegen opgl
MXPA04009681A (es) 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.

Also Published As

Publication number Publication date
KR100496063B1 (ko) 2005-06-21
EP1657255B1 (en) 2014-07-30
CA2257247C (en) 2012-09-11
ATE328006T1 (de) 2006-06-15
WO1998046644A1 (en) 1998-10-22
RU2238949C2 (ru) 2004-10-27
JP2005176847A (ja) 2005-07-07
CY2010017I1 (el) 2011-02-02
HU0800628D0 (en) 2010-06-28
ES2263204T5 (es) 2013-10-14
US20120329671A1 (en) 2012-12-27
CN1222917A (zh) 1999-07-14
NO2010021I1 (no) 2011-01-10
DE122010000049I1 (de) 2011-05-05
ES2263204T3 (es) 2006-12-01
US20080187540A9 (en) 2008-08-07
JP4878616B2 (ja) 2012-02-15
NO2010021I2 (no) 2015-03-09
AU735355B2 (en) 2001-07-05
KR20040004509A (ko) 2004-01-13
US7449185B2 (en) 2008-11-11
JP2009013177A (ja) 2009-01-22
IL127115A (en) 2013-08-29
US20100136011A1 (en) 2010-06-03
JP2013139465A (ja) 2013-07-18
EP0911342B1 (en) 2006-05-31
US20030208045A1 (en) 2003-11-06
NO322632B1 (no) 2006-11-06
JP4355357B2 (ja) 2009-10-28
NZ332995A (en) 2000-07-28
JP2012041345A (ja) 2012-03-01
EP2336168A1 (en) 2011-06-22
JP5593407B2 (ja) 2014-09-24
EP1657255A1 (en) 2006-05-17
AU735355C (en) 1998-11-11
PT911342E (pt) 2006-08-31
IL127115A0 (en) 1999-09-22
US20070009520A1 (en) 2007-01-11
CY2010017I2 (el) 2012-01-25
US20030176647A1 (en) 2003-09-18
JP3523650B2 (ja) 2004-04-26
JP3935861B2 (ja) 2007-06-27
HUP0000717A2 (hu) 2000-06-28
LU91759I9 (ja) 2019-01-02
US20050003457A1 (en) 2005-01-06
EP0911342A1 (en) 1999-04-28
HU229476B1 (en) 2014-01-28
DE69834699T2 (de) 2007-05-16
AU6851898A (en) 1998-11-11
CA2257247A1 (en) 1998-10-22
DK0911342T4 (da) 2013-07-29
CN1138786C (zh) 2004-02-18
US20050208580A1 (en) 2005-09-22
US7527790B2 (en) 2009-05-05
DE69834699D1 (de) 2006-07-06
NO985848L (no) 1999-02-15
DE69834699T3 (de) 2013-11-14
HUS1400027I1 (hu) 2016-10-28
CA2781623A1 (en) 1998-10-22
EP0911342A4 (en) 2002-11-27
JP4230993B2 (ja) 2009-02-25
US7192718B2 (en) 2007-03-20
JP5285751B2 (ja) 2013-09-11
HU229841B1 (en) 2014-09-29
DK0911342T3 (da) 2006-08-21
NO985848D0 (no) 1998-12-14
EP0911342B2 (en) 2013-05-22
JP2009029834A (ja) 2009-02-12
FR10C0048I1 (ja) 2011-01-14
JP2004041195A (ja) 2004-02-12
LU91759I2 (fr) 2011-01-24

Similar Documents

Publication Publication Date Title
FR10C0048I2 (fr) Nouvelle proteine et methode de production associee
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
ES2173922T3 (es) Polipeptidos de la familia del gen de la semaforina.
DK0383504T3 (da) Decahydroisoquinolin-derivater, fremgangsmåde til fremstilling deraf og anvendelse deraf som medicin
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
DK95291D0 (da) Rekombinante dna-molekyler
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
EP1517144A3 (en) Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
DE69328060T2 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
AU4136797A (en) Novel semaphorin gene: semaphorin y
DE69637941D1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
WO2001064876A3 (en) Human schizophrenia gene
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
ATE556135T1 (de) Neues protein
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
TH62973A (th) กรดนิวคลีอิค และพอลิเพพไทด์ตัวรับชนิดใหม่